RxDoctor Payments DataLook up a doctor →

Christi Pendergraft, MD

Neurology · Oklahoma City, OKNPI 1184945248

Payments from drug & device makers

$72,774in general payments, 2019–2025

Across 952 payments — averaging $76.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$57K
  • AbbVie$3K
  • Promius Pharma LLC$1K
  • Lundbeck LLC$1K
  • Lilly USA, LLC$963
  • Pfizer$835
  • plus $8K from 45 others

What the payments were for

  • Consulting fees$1,0001%
  • Speaking & faculty fees$52,49072%
  • Travel & lodging$2,5924%
  • Food & beverage$16,65523%
  • Education$360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,774 in reported general payments places this provider in the 80th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$52,019
Medicare patients
124
Services billed
2,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm91$70,005
BotoxOnabotulinumtoxina30$39,158
UbrelvyUbrogepant25$37,348
Nurtec OdtRimegepant Sulfate32$37,297
Ajovy AutoinjectorFremanezumab-Vfrm25$19,512
Aimovig AutoinjectorErenumab-Aooe15$11,255
Candesartan Cilexetil111$3,847
Pregabalin86$3,740
Naproxen28$2,603
Carbamazepine ErCarbamazepine21$2,499
Gabapentin110$2,223
Lacosamide13$1,561
Zonisamide34$1,137
Prochlorperazine Maleate49$851
Oxcarbazepine20$818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy$3,495$76,50655 claims
PfizerNurtec Odt$835$37,29732 claims
Upsher-smith Laboratories LLCTopiramate$59$36143 claims
Almatica Pharma LLCSertraline Hcl$12$4515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 152 neurology providers in Oklahoma.

Other neurology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →